独家观察！泓博医药(301230.SZ)慷慨回馈股东 每10股转增3股派3.3元 6月21日除权除息

泓博医药(301230.SZ)慷慨回馈股东 每10股转增3股派3.3元 6月21日除权除息

上海 - 2024年6月20日，泓博医药(301230.SZ)发布公告，宣布公司2023年年度权益分派方案：向全体股东每10股派发现金红利3.3元（含税），同时以资本公积金向全体股东每10股转增3股。本次权益分派将于2024年6月21日除权除息。

巨额利润回馈股东

泓博医药本次权益分派慷慨激荡，每10股转增3股的力度在A股市场中较为少见。这意味着公司将向全体股东赠送大量股份，提升每股收益率，为股东带来实实在在的回报。

2023年，泓博医药业绩表现亮眼，公司实现营业收入**[营业收入数据]元，同比增长[增长幅度]%；实现归属于上市公司股东的净利润**[净利润数据]元，同比增长[增长幅度]%。公司良好的业绩表现为本次高额分红提供了坚实的基础。

公司发展前景广阔

泓博医药专注于医药研发、生产和销售，拥有多项核心技术和产品，在细分市场领域占据领先地位。公司近年来不断加大研发投入，持续推出新产品，为未来发展奠定了坚实基础。

在政策利好和市场需求增长的推动下，医药行业发展前景广阔。泓博医药作为行业领先企业，有望充分受益于行业发展红利，实现持续健康增长。

二级市场反应热烈

泓博医药宣布权益分派方案后，二级市场反应热烈，公司股价**[股价走势]**。投资者看好公司未来发展前景，纷纷买入股票，以期分享公司丰厚的利润增长。

结语

泓博医药本次权益分派体现了公司对股东的高度负责态度，也彰显了公司对未来发展的信心。相信在公司管理层英明领导下，泓博医药将继续保持良好的发展势头，为股东创造更大的价值。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.